<DOC>
	<DOCNO>NCT02457858</DOCNO>
	<brief_summary>In study , investigator hypothesize addition antioxidant BMX-010 perfusion solution , digestion solution culture medium islet isolation process , lead great preservation islet mass metabolic function , improve islet yield , viability , functional potency . This pilot study involve 10 participant islet transplant wait list Clinical Islet Transplant Program . All participant receive islet isolated medication BMX-010 . This assess primary safety BMX-010 pancreata islet . BMX-010 use islet isolation process , give participant medication .</brief_summary>
	<brief_title>Islet Isolation Using MnTE-2-PyP ( BMX-010 ) - Pilot Study</brief_title>
	<detailed_description>Islet Transplantation procedure use people difficult control Type 1 Diabetes . Insulin produce cell ( islet ) isolate deceased donor pancreas . After cell carefully isolate donor pancreas , islet transplant recipient 's liver . These transplanted islet may produce insulin . One challenge islet transplant death islet cell isolation storage await transplant . This cause , part , inflammation `` oxidization '' islet tissue . Oxidization process cause chemical stress live cell . We look medication would reduce inflammation , reduce oxidization minimize cell death isolation process . BMX-010 new drug believe help fight oxidization . It antioxidant show lab study help islet cell survive isolation keep healthy functioning . BMX-010 use human islet transplant Canada study . BMX-010 use patient need pancreas remove - islet isolate treated BMX-010 , transplant back patient ( auto-islet transplant ) . These result promise significant side-effects report . There also study use human islet , treat BMX-010 , transplant mouse . In study , 10 patient receive islet treat BMX-010 . This assess primary safety BMX-010 pancreata islet . For pancreata islet treat BMX-010 , BMX-010 add step pancreas perfusion , pancreas digestion islet culture . Participants study receive islet transplant standard care islet transplant aspects peri- post-transplant management include immunosuppression . Islet transplant patient follow part standard care , therefore data collect study measure part routine clinical care , require extra study specific clinic visit . We review data collect day 30 post-transplant include follow : patient graft survival data , biochemical data routine blood work , routine cause imaging , metabolic testing , initiation intervention treat complication , report adverse serious adverse event .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>To eligible participant must type 1 diabetes mellitus ( T1DM ) 5 year , complicate least 1 follow situation persist despite intensive insulin management effort : . Reduced awareness hypoglycemia , define absence adequate autonomic symptom plasma glucose level &lt; 3.0 mmol/L , indicate , 1 episode severe hypoglycemia require third party assistance within 12 month , Clarke score ≥4 , HYPO score ≥1,000 , lability index ( LI ) ≥400 combine HYPO/LI &gt; 400/ &gt; 300 . b. Metabolic instability , characterize erratic blood glucose level interfere daily activity 1 hospital visit diabetic ketoacidosis last 12 month . Participants must capable understand purpose risk study must sign statement informed consent . 1 . History enrollment islet transplant trial ( discretion investigator ) . 2 . Severe coexist cardiac disease , characterize one condition : ( ) recent ( within past 6months ) myocardial infarction ; ( b ) leave ventricular ejection fraction &lt; 30 % ; ( c ) evidence ischemia functional cardiac exam . 3 . Active alcohol substance abuse , include cigarette smoking ( must abstinent 6 month prior list transplant ) . 4 . Psychiatric disorder make subject suitable candidate transplantation , ( e.g. , schizophrenia , bipolar disorder , major depression unstable uncontrolled current medication ) . 5 . History nonadherence prescribe regimen . 6 . Active infection include Hepatitis C , Hepatitis B , HIV , TB ( subject positive PPD perform within one year enrollment , history adequate chemoprophylaxis ) . 7 . Any history , current malignancy except squamous basal skin cancer . 8 . BMI &gt; 35 kg/m2 screen visit . 9 . Age le 18 great 68 year . 10 . Measured glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73 m2 . 11 . Presence history macroalbuminuria ( &gt; 300 mg/g creatinine ) . 12 . Clinical suspicion nephritic ( hematuria , active urinary sediment ) rapidly progress renal impairment ( e.g . Increase serum creatinine 25 % within last 36 month ) . 13 . Baseline Hb &lt; 105g/L ( &lt; 10.5 g/dL ) woman , &lt; 120 g/L ( &lt; 12 g/dL ) men . 14 . Baseline screen liver function test outside normal range , exception uncomplicated Gilbert 's Syndrome . An initial LFT panel value &gt; 1.5 time upper limit normal ( ULN ) exclude patient without retest ; retest value ULN 1.5 time ULN make , value remain elevated normal limit , patient exclude . 15 . Untreated proliferative retinopathy . 16 . Positive pregnancy test , intent future pregnancy male subject ' intent procreate , failure follow effective contraceptive measure , presently breastfeed . 17 . Evidence significant sensitization PRA ( discretion investigator ) . 18 . Insulin requirement &gt; 1.0 U/kg/day 19 . HbA1C &gt; 12 % . 20 . Uncontrolled hyperlipidemia [ fast LDL cholesterol &gt; 3.4 mmol/L ( 133 mg/dL ) , treat untreated ; and/or fast triglyceride &gt; 2.3 mmol/L ( 90 mg/dL ) ] . 21 . Under treatment medical condition require chronic use steroid . 22 . Use coumadin anticoagulant therapy ( except aspirin ) subject PT/INR &gt; 1.5 . 23 . Untreated Celiac disease . 24 . Patients Graves disease exclude unless previously adequately treated radioiodine ablative therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Islet Transplant</keyword>
</DOC>